UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041237
Receipt number R000047089
Scientific Title A Prospective Observational Study on the Efficacy of detecting circulating tumor DNA by Means of a Next-Generation Sequencer Using Cell-Free DNA in lung cancer patients
Date of disclosure of the study information 2020/07/28
Last modified on 2024/02/02 11:25:15

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Prospective Observational Study on the Efficacy of detecting circulating tumor DNA by Means of a Next-Generation Sequencer Using Cell-Free DNA in lung cancer patients

Acronym

cfDNA analysis in lung cancer patients

Scientific Title

A Prospective Observational Study on the Efficacy of detecting circulating tumor DNA by Means of a Next-Generation Sequencer Using Cell-Free DNA in lung cancer patients

Scientific Title:Acronym

cfDNA analysis in lung cancer patients

Region

Japan


Condition

Condition

Non-small cell lung cancer

Classification by specialty

Chest surgery

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

The purpose of this research is to verify the effectiveness of molecular staging detecting circulating tumor DNA analysis by means of a next-generation sequencer using cell free DNA (cfDNA) derived from lung cancer patients.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

The purpose of this research is to verify the effectiveness of detecting circulating tumor DNA analysis by means of a next-generation sequencer using cell free DNA (cfDNA) derived from lung cancer patients and to verify the relation to the postoperative recurrence.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Non-small cell lung cancer patients clinical stage IB-IVA.
2. 20 years old or above
3. With written informed consent.

Key exclusion criteria

1. Positive for infection (HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody)
2. Cases in which the principal investigator determined that the subject was inappropriate

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Ichiro
Middle name
Last name Yoshino

Organization

Graduate School of Medicine,Chiba University

Division name

Department of General Thoracic Surgery

Zip code

2608670

Address

1-8-1 Inohana, chuo-ku, Chiba, Japan

TEL

043-222-7171

Email

iyoshino@faculty.chiba-u.jp


Public contact

Name of contact person

1st name Kazuhisa
Middle name
Last name Tanaka

Organization

Graduate School of Medicine,Chiba University

Division name

Department of General Thoracic Surgery

Zip code

2608670

Address

1-8-1 Inohana, chuo-ku, Chiba, Japan

TEL

043-222-7171

Homepage URL


Email

kaztanaka-ths@umin.ac.jp


Sponsor or person

Institute

Chiba University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Ministry of education

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Chiba University Hospital Clinical Research Center

Address

1-8-1 Inohana Chuo-ku Chiba 260-8677, JAPAN

Tel

043-226-2734

Email

chibacrc@mac.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 07 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

15

Results

15 patients were enrolled in this study.
We are observing their postoperative course.
We have begun analyzing specimens mainly from recurrent cases.

Results date posted

2022 Year 02 Month 28 Day

Results Delayed

Delay expected

Results Delay Reason

There were few recurrences.

Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2020 Year 06 Month 25 Day

Date of IRB

2020 Year 06 Month 26 Day

Anticipated trial start date

2020 Year 06 Month 26 Day

Last follow-up date

2025 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2025 Year 06 Month 30 Day


Other

Other related information

Observational study


Management information

Registered date

2020 Year 07 Month 28 Day

Last modified on

2024 Year 02 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047089


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name